Ideaya Biosciences Inc. is a clinical-stage oncology-focused precision medicine company. The company's main focus is on the discovery and development of targeted therapeutics for patients with genetically defined cancers. Ideaya Biosciences utilizes its proprietary product engine, comprised of gene regulatory and protein-protein interaction networks, to identify new oncology targets and rational drug combinations for both monotherapy and combination therapy.
The company's lead product candidate is IDE196, an orally available protein kinase C inhibitor for the treatment of metastatic uveal melanoma. Additionally, Ideaya Biosciences is advancing multiple preclinical programs, including programs targeting synthetic lethality, immuno-oncology pathways, and other oncology targets.
Ideaya Biosciences has partnerships and collaborations with various companies and institutions, including GlaxoSmithKline, Novartis, Pfizer, and the Parker Institute for Cancer Immunotherapy.
The company is headquartered in South San Francisco, California, and was founded in 2015.
Ideaya Biosciences Inc. is a clinical-stage oncology-focused precision medicine company. The company's main focus is on the discovery and development of targeted therapeutics for patients with genetically defined cancers. Ideaya Biosciences utilizes its proprietary product engine, comprised of gene regulatory and protein-protein interaction networks, to identify new oncology targets and rational drug combinations for both monotherapy and combination therapy.